18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease
暂无分享,去创建一个
A. S. Brandt | M. Forsting | J. Theysohn | T. Poeppel | A. Bockisch | L. Umutlu | M. Ruhlmann | Verena Ruhlmann | J. Grüneisen
[1] Philip M Robson,et al. Quantitative carotid PET/MR imaging: clinical evaluation of MR-Attenuation correction versus CT-Attenuation correction in (18)F-FDG PET/MR emission data and comparison to PET/CT. , 2015, American journal of nuclear medicine and molecular imaging.
[2] Gerald Antoch,et al. Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[3] A. S. Brandt,et al. Diffusion-weighted MRI findings of treated and untreated retroperitoneal fibrosis. , 2014, Diagnostic and interventional radiology.
[4] M. Forsting,et al. Correlation of Standardized Uptake Value and Apparent Diffusion Coefficient in Integrated Whole-Body PET/MRI of Primary and Recurrent Cervical Cancer , 2014, PloS one.
[5] Habib Zaidi,et al. Detection and quantification of focal uptake in head and neck tumours: 18F-FDG PET/MR versus PET/CT , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[6] M. Forsting,et al. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI. , 2013, European journal of radiology.
[7] Blanca Paño Brufau,et al. Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.
[8] A. S. Brandt,et al. An Aid to Decision-Making in Therapy of Retroperitoneal Fibrosis: Dynamic Enhancement Analysis of Gadolinium MRI , 2013, Journal of clinical medicine research.
[9] Uwe Pietrzyk,et al. Does PET/MR in human brain imaging provide optimal co-registration? A critical reflection , 2012, Magnetic Resonance Materials in Physics, Biology and Medicine.
[10] M. Halaç,et al. FDG PET/CT in monitoring treatment of retroperitoneal fibrosis. , 2012, Revista espanola de medicina nuclear e imagen molecular.
[11] O. Ratib,et al. 18F-FDG PET/CT and Contrast-Enhanced CT in a One-Stop Diagnostic Procedure: A Better Strategy for Management of Patients Suffering From Retroperitoneal Fibrosis? , 2012, Clinical nuclear medicine.
[12] G. Treglia,et al. [18F]FDG-PET/CT in patients affected by retroperitoneal fibrosis: a bicentric experience , 2012, Japanese Journal of Radiology.
[13] P. Messa,et al. The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. , 2012, European journal of nuclear medicine and molecular imaging.
[14] A. S. Brandt,et al. MR evaluation of retroperitoneal fibrosis. , 2011, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
[15] G. Piccoli,et al. Positron emission tomography as a tool for the 'tailored' management of retroperitoneal fibrosis: a nephro-urological experience. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] T. Hendriksz,et al. (18)F-fluorodeoxyglucose position emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. , 2010, European journal of internal medicine.
[17] A. Matsuzaki,et al. 18F-Fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of idiopathic retroperitoneal fibrosis associated with mediastinal fibrosis , 2010, Annals of nuclear medicine.
[18] M. Magrey,et al. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? , 2009, Arthritis and rheumatism.
[19] M. Uder,et al. Ormond’s Disease or Secondary Retroperitoneal Fibrosis? An Overview of Retroperitoneal Fibrosis , 2009, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.
[20] Nassir Navab,et al. Tissue Classification as a Potential Approach for Attenuation Correction in Whole-Body PET/MRI: Evaluation with PET/CT Data , 2009, Journal of Nuclear Medicine.
[21] J. Peterson,et al. Hypermetabolic activity in patients with active retroperitoneal fibrosis on F-18 FDG PET: report of three cases , 2007, Annals of nuclear medicine.
[22] 金子 文成,et al. 長時間歩行時の下肢筋の活動状態:[ 18 F]fluorodeoxyglucoseを用いたPositron Emission Tomographyによる検討 , 2008 .
[23] T. Geoghegan,et al. Imaging and intervention of retroperitoneal fibrosis. , 2007, Australasian radiology.
[24] A. S. Brandt,et al. ["Retroperitoneal Fibrosis" (RPF) Urologic Cooperation and Research Project]. , 2007, Der Urologe. Ausg. A.
[25] N. Salkind. Encyclopedia of Measurement and Statistics , 2006 .
[26] A. Vaglio,et al. Retroperitoneal fibrosis , 2006, The Lancet.
[27] Thomas Beyer,et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] A. Vaglio,et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar" ? A study using 18F-fluorodeoxyglucose positron emission tomography. , 2005, Clinical and experimental rheumatology.
[29] G. Boustead,et al. Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis. , 2002, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.
[30] T. Fernández-Villa,et al. Retroperitoneal fibrosis: typical and atypical manifestations. , 2000, The British journal of radiology.
[31] Russo Em,et al. Typical and atypical manifestations of celiac disease , 1979 .
[32] T. Asch,et al. Retroperitoneal fibrosis. An anatomic and radiologic review with a report of four new cases and an explanation of pathogenesis. , 1960, Radiology.